severe asthma market
Sep 01, 2025
Mapping the Top Asthma Therapies: Inhaled Blockbusters and Injectable Powerhouses
Asthma: A Global Burden Driving Therapeutic Breakthroughs Asthma is a chronic inflammatory condition of the airways characterized by variable symptoms including wheezing, shortness of breath, chest tightness, and cough. It involves underlying airway inflammation, bronchial hyperresponsiveness, and reversible air...
Read More...
May 28, 2024
AstraZeneca’s Tropion-Lung01 Phase III Trial Positive Outcomes; Biogen’s LEQEMBI South Korea Approval; AltruBio’s $225M Series B Funding; GSK’s Depemokimab Positive Phase III Severe Asthma Results; Roche’s Inavolisib FDA Breakthrough Therapy Designation
The Tropion-Lung01 Phase III Trial Reveals that Datopotamab Deruxtecan Significantly Enhanced Overall Survival in Advanced Nonsquamous NSCLC Patients Compared to Chemotherapy The high-level overall survival (OS) results from the TROPION-Lung01 Phase III trial, which had previously met the dual primary endpoint o...
Read More...
Sep 12, 2022
How Emerging Pipeline Therapies Will Unfold the Severe Asthma Treatment Market Dynamics?
Key Highlights Tezspire (tezepelumab) with no phenotypic (eosinophilic or allergic) or biomarker restriction will be the new game-changer in the severe asthma marketDepemokimab is an excellent market replacement for GSKs’ Nucala as of its improved binding affinity and longer duration of action as a single doseNo...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
